GSK invests $139M to expand biopharmaceutical plant in Rockville, Maryland

GSK announced a $139 million investment to expand its biopharmaceutical manufacturing site in Rockville, MD, to increase bulk drug substance production for BENLYSTA by close to 50%.

“We are so pleased that on the first day of Lupus Awareness Month we are able to announce this expansion in Rockville, increasing our ability to provide this important medicine to patients.”us.gsk.com

• 1 source
• us.gsk.comGSK invests $139 million to expand production capacity for BENLYSTA (belimumab) in Rockville, MD | GSK USMay 5, 2017

Summarized from public sources; check the original articles before acting on it.